3.18
6.74%
-0.23
Handel nachbörslich:
3.25
0.07
+2.20%
AC Immune SA Aktie (ACIU) Neueste Nachrichten
Analysts Issue Forecasts for AC Immune SA's FY2028 Earnings (NASDAQ:ACIU) - Defense World
Defense World
Q3 2024 EPS Estimates for AC Immune SA (NASDAQ:ACIU) Reduced by Analyst - Defense World
Defense World
Leerink Partnrs Weighs in on AC Immune SA's FY2028 Earnings (NASDAQ:ACIU) - MarketBeat
MarketBeat
AC Immune and Takeda Pharma ink $2.1 B deal for immunotherapy to delay Alzheimer's progression - BSA bureau
BSA bureau
AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
Equities Analysts Offer Predictions for AC Immune SA's FY2025 Earnings (NASDAQ:ACIU) - Defense World
Defense World
New Forecasts: Here's What Analysts Think The Future Holds For AC Immune SA (NASDAQ:ACIU) - Yahoo New Zealand News
Yahoo New Zealand News
Research Analysts Set Expectations for AC Immune SA's FY2025 Earnings (NASDAQ:ACIU) - MarketBeat
MarketBeat
Top Ranked Momentum Stocks to Buy for January 30th - Yahoo News UK
Yahoo News UK
Takeda agrees to develop active immunotherapy for Alzheimer's - Marketscreener.com
Marketscreener.com
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study - Yahoo Movies UK
Yahoo Movies UK
Takeda, AC Immune Ink Exclusive Agreement for Alzheimer's Immunotherapy - Contract Pharma
Contract Pharma
AC Immune (NASDAQ:ACIU) spikes 38% this week, taking one-year gains to 57% - Simply Wall St
Simply Wall St
AC Immune and Takeda ink US$2.1bn biobucks deal - European Biotechnology News
European Biotechnology News
AC Immune's Alzheimer's vaccine draws $2.2B in Takeda deal - BioWorld Online
BioWorld Online
Gold Down Over 1%; AC Immune Shares Spike Higher - AC Immune (NASDAQ:ACIU) - Benzinga
Benzinga
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? - AC Immune (NASDAQ:ACIU), - Benzinga
Benzinga
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? - Investing.com UK
Investing.com UK
Takeda shells out $100m to license AC Immune's Phase II Alzheimer's therapy - Pharmaceutical Technology
Pharmaceutical Technology
Alzheimer's vaccine licensing deal boosts AC Immune - MSN
MSN
Takeda and AC Immune ink $2.1 billion Alzheimer's therapy deal - Investing.com
Investing.com
AC Immune rockets 47% on Alzheimer's therapy deal with Takeda (NASDAQ:ACIU) - Seeking Alpha
Seeking Alpha
Sizing Up a Micro-Cap Biotech for a Speculative Play - TheStreet
TheStreet
Alzheimer’s vaccine licensing deal boosts AC Immune - MarketWatch
MarketWatch
AC Immune's (ACIU) Share Price Surges Pre-Market - Stocks Telegraph
Stocks Telegraph
AC Immune jumps on licensing deal with Takeda for Alzheimer's disease treatment - XM
XM
Takeda and AC Immune ink $2.1 billion Alzheimer's therapy deal By Investing.com - Investing.com
Investing.com
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Yahoo Finance
Yahoo Finance
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid ... - Manchestertimes
Manchestertimes
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid ... - Business Wire
Business Wire
AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies Canada
Yahoo Movies Canada
AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why - Yahoo Singapore News
Yahoo Singapore News
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by StockNews.com - MarketBeat
MarketBeat
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Singapore News
Yahoo Singapore News
AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates - Yahoo New Zealand News
Yahoo New Zealand News
AC Immune SA (NASDAQ:ACIU) Short Interest Update - Defense World
Defense World
AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet - Simply Wall St
Simply Wall St
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth - Simply Wall St
Simply Wall St
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
GlobeNewswire Inc.
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update - Yahoo Finance
Yahoo Finance
ACI-19764 is a potent brain-penetrant NLRP3 inhibitor for neurological disorders - BioWorld Online
BioWorld Online
AD/PD 2024: AC Immune looks to second part of Phase II Parkinson's vaccine trial - Clinical Trials Arena
Clinical Trials Arena
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 - Yahoo Finance
Yahoo Finance
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Zacks Investment Research
5 Little-Known Penny Stocks With Massive Upside Potential - Insider Monkey
Insider Monkey
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
Zacks Investment Research
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
Zacks Investment Research
Roche jumps ship on AC Immune - European Biotechnology News
European Biotechnology News
AC Immune stock slips as Roche ends Alzheimer's deal (NASDAQ:ACIU) - Seeking Alpha
Seeking Alpha
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
Zacks Investment Research
Kapitalisierung:
|
Volumen (24h):